Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK plus ) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). Mok, T., Spigel, D., Felip, E., deMarinis, F., Ahn, M., Groen, H. M., Wakelee, H. A., Hida, T., Crino, L., Nishio, M., Scagliotti, G. V., Branle, F., Emeremni, C., Quadrigli, M., Zhang, J., Shaw, A. AMER SOC CLINICAL ONCOLOGY. 2015
View details for Web of Science ID 000358036901771